EIP
HAE icon

Easterly Investment Partners’s Haemonetics HAE Stock Holding History

Easterly Investment Partners’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.25M Buy
43,307
+12,185
+39% +$783K 0.17% 115
2026
Q1 		$1.72M Buy
31,122
+1,432
+5% +$93.3K 0.13% 95
2025
Q4 		$2.38M Sell
29,690
-180
-0.6% -$12.1K 0.15% 117
2025
Q3 		$1.46M Buy
29,870
+30
+0.1% +$1.86K 0.1% 134
2025
Q2 		$2.23M Sell
29,840
-991
-3% -$65.6K 0.16% 112
2025
Q1 		$1.96M Buy
+30,831
New +$2.1M 0.16% 111

Other funds holding HAE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Easterly Investment Partners's HAE Position: Q2 2026 in Review

Easterly Investment Partners increased its Haemonetics (HAE) stake by 39% in Q2 2026, buying an estimated $783K and bringing the position to 43,307 shares worth $3.25M. The position accounts for 0.17% of the portfolio, ranked #115.

Easterly Investment Partners first reported a position in HAE in Q1 2025 and has held it in 6 quarters since. 329 funds tracked by Wall St. Rank hold HAE as of Q2 2026.

  • Easterly Investment Partners held 43,307 shares of Haemonetics worth $3.25M as of Q2 2026.
  • Easterly Investment Partners bought 12,185 Haemonetics shares in Q2 2026, an estimated $783K.
  • Haemonetics made up 0.17% of Easterly Investment Partners's portfolio in Q2 2026, its #115 holding.
  • Easterly Investment Partners first reported a position in Haemonetics in Q1 2025 and has held it in 6 quarters since.
  • 329 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.

Based on Easterly Investment Partners's 13F filing for Q2 2026, filed 23 Jul 2026.